Expert Interview
Delving into the impact of Medtronic’s Hugo robotic-assisted surgery system on urologic treatment patterns following its FDA IDE trial success
Ticker(s): MDTInstitution: One Urology
- Urologist at One Urology in California.
- Currently manages 125-200 patients with bladder cancer.
- Clinical focus on urologic cancer, stone disease, incontinence, erectile dysfunction, men’s health, and infertility.
Can you describe your current experience with robotic-assisted urologic procedures, and how new platforms like Medtronic’s Hugo compare to existing systems
Added By: dami_adminWhat are your initial impressions of the clinical data supporting the Hugo system, and do you foresee any barriers or advantages in adopting this platform within your institution or practice?
Added By: dami_adminHow do you anticipate the entry of alternative surgical robotic systems, like Hugo, will influence procedure volume, training, cost considerations, and patient outcomes in urologic surgery?
Added By: dami_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
